nature › nature medicine › articles › article
10 Years of Impact SEERAVE EVA REES
As a retired oil trader, I want to tell you why I care about the microbiome and cancer, and why I founded Seerave a decade ago.
In 2006, my wife, Eva Rees, had a small melanoma lesion removed from her shoulder. We considered it insignificant and forgot all about it, but seven years later, in late 2013, she was found to have a large tumour in her lung. It transpired that this was Stage 4 metastatic melanoma, which meant that the cancer cells were circulating throughout her system. This was before the advent of immunotherapy, and because she had an unusual mutation, there was no targeted treatment. She was simply told to go home with the oncologist’s words that there was nothing more we could do for you. Her prognosis was 10 to 12 months. So, at the ripe age of 70, I decided very quickly to retire from the oil company I co-founded and start trying to figure out what I could do to help keep my wife alive.
Around this time, the burgeoning science of the microbiome was making its presence felt, and I became convinced that the nutrition-microbiome-immunity-cancer axis was one we should pursue. But how?
With the shares of my company as an endowment, I set up Seerave. Serendipity then kicked in. I met two wonderful researchers, a microbiologist and a tumour immunologist, persuaded them to join Seerave, and this then provided us with a scientific backbone and made Seerave what it is today. I subsequently met pioneering and inspirational oncologists who gave us their scientific backing and whose research we started to support.
Returning to the family, my wife survived six years after her surgery until a relapse in 2020, when seven tumours were found in her upper body. Around the same time, my son-in-law, Jonas, was diagnosed with kidney cancer. Both these cancers were then treatable with revolutionary immunotherapy drugs, which harnessed the patient’s own immune system to fight the disease.
However, one of the biggest questions we have yet to answer is why do only some 40% of patients respond to this treatment? My wife responded strongly. Jonas tragically did not, and he passed away at the young age of 47. This galvanised us to focus on what we could do in the immediate term to help people in the same situation.
Throughout this period, compelling evidence was mounting that much of the answer lies with the myriads of organisms that live in our gut that comprise our microbiome, and their effect on the immune system. And yet, very little of this new research had penetrated mainstream oncology practice.
How might the microbiome influence cancer and immunotherapy?
First, a reminder: we evolved from microbes, amongst microbes, and in the world of their making
here
If life’s 3.8 billion years were a single day, humans would arrive in the last 7 seconds
We Live in a World of Microbes
They are intrinsic to our existence, and to our biology as any organ
As Copernicus did when he shifted our perspective to a heliocentric model of the universe, this insight invites us to reconsider a human-centred model of biology to one that revolves around microbes
There are 100x more microbial genes than human genes in your body, and we rely on them to perform functions that are not encoded in our own DNA
- Extract energy and nutritional value from our food
- Defend against diseases
- Steer the development of our organs
- Train and influence our immune system, balancing pro-inflammatory and anti-inflammatory states
- Influence our nervous system and mood
- And more
- P. Syringae seeds ice Microbes trigger rain and snow
- Microbes ferment our food including bread, cheese, yogurt, kimchi
- 100x more microbial genes than human genes in your body
- Nitrogen fixers feed all of life Only microbes could fix nitrogen before 1913
- Cyanobacteria produce O2 Microbes generate half of Earth’s oxygen today
Disruptions to our microbiome have been linked to diseases “of modernity”
- Anxiety / Depression
- Autism Spectrum Disorder
- Allergies
- Cancer
- Cardiovascular Disease
- COPD & Asthma
- Obesity & Diabetes
- Liver Diseases
- Antibiotic-Resistant Infection
- Inflammatory Bowel Disease
- Atopic Dermatitis
- Rheumatoid Arthritis
disease Over-reactive
immune system Under-reactive
immune system Cancer
Seerave’s purpose is to
improve outcomes and enhance quality of life for every patient by integrating the microbiome and its role in immune system performance into comprehensive cancer care
Our Thesis
At the frontier of oncology, clinicians are using patients’ own immune systems to treat cancer.
We believe that these immunotherapies hold great promise, and that the microbiome is key to realising the full potential of the immune system to cure disease.
Did You Know?
Patients who took antibiotics prior to immunotherapy had roughly half the chance of surviving beyond two years
Without antibioticsWith antibiotics
Our network’s insights on how the microbiome influences cancer outcomes
Perturbed microbiome can undermine patient outcomes
› NPJ Precis Oncol. 2024 Jul 16;8(1):143. doi: 10.1038/s41698-024-00630-w.
Review › Cancer Cell. 2026 Nov 9;44(11):2132-2153. doi: 10.1016/j.ccell.2026.09.012. Epub 2026 Oct 27.
Restoring the microbiome can improve patient outcomes
› Science. 2018 Jan 5;359(6371):91-97. doi: 10.1126/science.aan3706. Epub 2017 Nov 2.
Multicenter Study › JAMA Oncol. 2023 May 1;9(5):705-709. doi: 10.1001/jamaoncol.2022.7753.
▸ Cancer Discov. 2022 Apr 1;12(4):1070-1087. doi: 10.1158/2159-8290.CD-21-0808
Our First Ten Years
Working to build the “oncobiome” field
We funded groundbreaking science
We convened experts across silos
Large meetings, intimate gatherings, peer mentoring, working groups, retreats of experts across disparate fields and geographies
Fellows Retreat, Berlin 2019
Milestone Moments
Reflections from the people who shaped this progress
Select a story to read it and hear from the people who lived it.Swipe through the years, tap a story to read it.
Strategic Goal
We are shifting focus from delivering insights
to transforming outcomes
Today
Data
Inform stronger and more practicable advice for doctors about the microbiome and cancer.
Next few years
Practice
Update best practice on antibiotic use and other microbiome modifiers in a cancer setting.
Future
Tools
Develop new tools to protect and restore the microbiome
Future
Tools
Develop new tools to protect and restore the microbiome
Data
Seerave Global Oncobiome Atlas
A living catalogue of clinical datasets at the intersection of immuno-oncology and microbiome science, powered by a core consortium of partners from the US, Canada and Europe. It grew out of the PRIMM initiative and the OncoBiome EU project.
- Goal
- Give visibility to existing and planned datasets, harmonise data across sites and generate robust evidence on how microbiome modifiers like antibiotics affect cancer therapies.
- Status
- Launched in June 2025 at the Paris Immuno-Oncology Conference. First use case: antibiotics and immunotherapy.
Practice
Microbiome & Cancer Working Group
An international initiative sponsored by Seerave and co-chaired by Dr. Arielle Elkrief (CHUM) and Dr. Jen Wargo (MD Anderson), bringing together experts across oncology, immunology, microbiology and public health.
- Goal
- Deliver clear, evidence-based recommendations on how the microbiome can improve outcomes for every cancer patient, and define a clear path for integrating microbiome science into clinical care.
- Status
- Launched in November 2025 at the Society for Immunotherapy of Cancer (SITC) annual meeting.
Tools
Florey Biosciences
A synthetic biology company spun out of the Wyss Institute at Harvard by Andrés Cubillos, Raphaël Gayet and Jim Collins. Its lead programme is a medical food based on an engineered yeast strain, taken alongside antibiotics.
- Goal
- Manage the damage antibiotics do to the gut microbiome, in line with our commitment to mitigate the impact of microbiome modifiers on cancer outcomes.
- Status
- Seerave Ventures made a pre-seed investment in October 2024 and supports Florey as a founding partner. Lead programme: FLR-101.
Protect the Microbiome
- Probiotic bioengineered to degrade antibiotics after they perform their therapeutic function, before they reach the gut microbiome
- Would allow patients to use antibiotics without compromising their gut microbiome
- Harvard Wyss Institute spinout (Collins Lab)
Restore the Microbiome
NewCo.
- Probiotic with a consortium of bacterial strains that together restore key metabolic functions of the microbiome after it has been perturbed
- All existing probiotics only restore a fraction of functionality
Microbes that can convert:
fatty acids
Our Partners